

Clinical trials of prasugrel

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
prasugrel vs clopidogrel			
JUMBO-TIMI 26 , 2005 n=650/254 follow-up: 30 days	Prasugrel 3 doses versus clopidogrel 300mg loading dose followed by 75 mg daily)	patients undergoing elective or urgent percutaneous coronary intervention	Parallel groups double blind
TRILOGY ACS (overall population) , 2012 [NCT00699998] n=4663/4663 follow-up: 17 months (median)	prasugrel 10 mg daily versus clopidogrel 75 mg daily	patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event	Parallel groups double-blind 52 countries
TRITON-TIMI 38 , 2007 [NCT00097591] n=6813/6795 follow-up:	prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months	patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention	Parallel groups double blind 30 countries
ACAPULCO <i>ongoing</i> n=NA	-	-	

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in patients with scheduled percutaneous coronary intervention at <http://www.trialresultscenter.org/go-Q170>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>
- New P2Y12 Inhibitors for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q455>

- antiplatelets drug for acute coronary syndrome in patients not initially planned for PCI at <http://www.trialresultscenter.org/go-Q652>

References

JUMBO-TIMI 26, 2005:

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. *Circulation* 2005 Jun 28;111:3366-73 [15967851]

TRILOGY ACS (overall population), 2012:

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. *Am Heart J* 2010;160:16-22.e1 [20598967] [10.1016/j.ahj.2010.04.022](https://doi.org/10.1016/j.ahj.2010.04.022)

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. *N Engl J Med* 2012 Aug 25;: [22920930] [10.1056/NEJMoa1205512](https://doi.org/10.1056/NEJMoa1205512)

TRITON-TIMI 38, 2007:

Antman EM, Wiviott SD, Murphy SA, Voitek J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. *J Am Coll Cardiol* 2008 May 27;51:2028-33 [18498956]

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357:2001-15 [17982182]

ACAPULCO, :

ongoing trial

Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthlmy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. *Thromb Haemost* 2010;103:213-23 [20062936] [10.1160/TH09-07-0482](https://doi.org/10.1160/TH09-07-0482)

2 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
prasugrel vs clopidogrel			

continued...

Trial	Treatments	Patients	Trials design and methods
TRITOM TIMI 38 (PCI subgroup) , 2009 n=1769/1765 follow-up:	prasugrel (60 mg loading, 10 mg maintenance) versus clopidogrel (300 mg loading, 75 mg maintenance)	subgroup of patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction	
JUMBO-TIMI 26 , 2005 n=650/254 follow-up: 30 days	Prasugrel 3 doses versus clopidogrel 300mg loading dose followed by 75 mg daily)	patients undergoing elective or urgent percutaneous coronary intervention	Parallel groups double blind
TRIGGER-PCI <i>ongoing</i> [NCT00910299] n=NA follow-up: 6 months	prasugrel one time 60-mg oral loading dose and 10-mg once daily oral maintenance dose up to 6 months versus clopidogrel 75-mg oral daily maintenance dose up to 6 months	patients With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent	Parallel groups double blind
Prasugrel and Bivalirudin vs Clopidogrel and Heparin			
BRAVE-4 <i>ongoing</i> [NCT00976092] n=NA follow-up:	Prasugrel + Bivalirudin versus Clopidogrel + Heparin	STEMI patients undergoing PPCI	

33

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- antithrombotics for percutaneous coronary intervention in patients with high residual platelet activity on clopidogrel at <http://www.trialresultscenter.org/go-Q469>

References

TRITOM TIMI 38 (PCI subgroup), 2009:

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet* 2009;373:723-31 [[19249633](https://doi.org/10.1016/S0140-6736(09)60441-4)]
[10.1016/S0140-6736\(09\)60441-4](https://doi.org/10.1016/S0140-6736(09)60441-4)

JUMBO-TIMI 26, 2005:

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. *Circulation* 2005 Jun 28;111:3366-73 [[15967851](https://doi.org/10.1161/CIRCULATIONAHA.105.563111)]

TRIGGER-PCI, :

ongoing trial NCT00910299

BRAVE-4, :

ongoing trial NCT00976092

Entry terms: bivalirudin, Hirulog-1 Hirulog Angiomax, prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efient